MassMutual Private Wealth & Trust FSB Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

MassMutual Private Wealth & Trust FSB grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,172 shares of the medical research company’s stock after purchasing an additional 169 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in IQVIA were worth $230,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of IQV. Capital Performance Advisors LLP purchased a new stake in IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the third quarter worth about $28,000. Avior Wealth Management LLC boosted its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. grew its holdings in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, UMB Bank n.a. raised its holdings in shares of IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after acquiring an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IQV. Barclays cut their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday. The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Stock Down 0.2 %

IQVIA stock opened at $205.37 on Thursday. The business has a fifty day moving average price of $199.53 and a 200-day moving average price of $221.30. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The stock has a market capitalization of $37.27 billion, a price-to-earnings ratio of 26.95, a PEG ratio of 2.01 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.